Correlation between serum estradiol in the follicular phase of the ovarian cycle and decay accelerating factor (DAF) expression on red blood cells and coxsackievirus B3-induced hemagglutination in young cycling women

American Journal of Reproductive Immunology

Volumn 51, Issue 2, 2004, Pages 180-187

  Sartini, Danielle ^a   Moussawi, Mohamad ^a   Sallam, Reem ^a   Bernstein, Ira ^a   Huber, Sally ^a  

^a UNIVERSITY OF VERMONT   (United States)

Author keywords

Coxsackievirus; Decay accelerating factor; Ovarian cycle

Indexed keywords

CD19 ANTIGEN; CELL RECEPTOR; COMPLEMENT; COMPLEMENT COMPONENT C3D RECEPTOR; DECAY ACCELERATING FACTOR; ESTRADIOL; GLYCOPROTEIN; GREEN FLUORESCENT PROTEIN;

ADULT; ARTICLE; B LYMPHOCYTE; BLOOD DONOR; COMPLEMENT INHIBITION; CONTROLLED STUDY; CORRELATION ANALYSIS; COXSACKIE VIRUS B3; ERYTHROCYTE; FEMALE; FLOW CYTOMETRY; FOLLICULAR PHASE; HUMAN; HUMAN EXPERIMENT; INFECTION SENSITIVITY; LEUKOCYTE; LUTEAL PHASE; NORMAL HUMAN; OVARY CYCLE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; VIRUS HEMAGGLUTINATION; VIRUS INFECTIVITY; VOLUNTEER;

EID: 1242285963     PISSN: 10467408     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.8755-8920.2003.00142.x     Document Type: Article

References (30)

1. Medof ME, Walter EL Rutgers JL, Knowles DM, Nussenzweig V: Identification of the complement decay-accelerating factor (DAF) on epithelium and glandular cells and in body fluids. J Exp Med 1987; 165:848-864.
2. Kinoshita T, Medof ME, Silber R, Nussenzweig V: Distribution of decay-accelerating factor in the peripheral blood of normal individuals and patients with paroxysmal nocturnal hemoglobinuria. J Exp Med 1985; 162:75-92.
3. Matthes T, Tullen E, Poole J, Banks J, Nagy M, Stelling MJ, Boehlen F, Michel M, Beris P, Hustinx H, Crew V, Daniels G: Acquired and transient RBC CD55 deficiency (Inab phenotype) and anti-IFC. Transfusion 2002; 42:1448-1457.
4. Medof ME, Lublin DM, Holers VM, Ayers DJ, Getty RR, Leykam JF, Atkinson JP, Tykocinski ML: Cloning and characterization of cDNAs encoding the complete sequence of decay-accelerating factor of human complement. Proc Natl Acad Sci U S A 1987; 84:2007-2011.
5. Fujita T, Inoue T, Ogawa K, Iida K, Tamura N: The mechanism of action of decay-accelerating factor (DAF). DAF inhibits the assembly of C3 convertases by dissociating C2a and Bb. J Exp Med 1987; 166:1221-1228.
6. Ito S, Tamura N, Fujita T: Effect of decay-accelerating factor on the assembly of the classical and alternative pathway C3 convertases in the presence of C4 or C3 nephritic factor. Immunology 1989; 68:449-452.
7. Sun X, Funk CD, Deng C, Sahu A, Lambris JD, Song WC: Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting. Proc Natl Acad Sci USA 1999; 96:628-633.
8. Morgan J, Spendlove I, Durrant LG: The role of CD55 in protecting the tumour environment from complement attack. Tissue Antigens 2002; 60:213-223.
9. Lin F, Kaminski HJ, Conti-Fine BM, Wang W, Richmonds C, Medof ME: Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection. J Clin Invest 2002; 110:1269-1274.
10. Verbakel CA, Van Duikeren S, De Bruin RW, Marquet RL, Ijzermans JN: Human decay-accelerating factor expressed on rat hearts inhibits leukocyte adhesion. Transpl Int 2003; 16:168-172.
11. Tosello A, Mary F, Amiot M, Bernard A, Mary D: Activation of T cells via CD55: recruitment of early components of the CD3-TCR pathway is required for IL-2 secretion. J Inflamm 1998; 48:13-27.
12. Shibuya K, Abe T, Fujita T: Decay-accelerating factor functions as a signal transducing molecule for human monocytes. J Immunol 1992; 149:1758-1762.
13. Shenoy-Scaria AM, Kwong J, Fujita T, Olszowy MW, Shaw AS, Lublin DM: Signal transduction through decay-accelerating factor. Interaction of glycosyl-phosphatidylinositol anchor and protein tyrosine kinases p56lck and p59fyn 1. J Immunol 1992; 149:3535-3541.
14. Shafren DR: Viral cell entry induced by cross-linked decay-accelerating factor. J Virol 1998; 72:9407-9412.
15. Shafren DR, Bates RC, Agrez MV, Herd RL, Burns GF, Barry RD: Coxsackieviruses B1, B3, and B5 use decay accelerating factor as a receptor for cell attachment. J Virol 1995, 69:3873-3877.
16. Bergelson JM, Mohanty JG, Crowell RL, St John NF, Lublin DM, Finberg RW: Coxsackievirus B3 adapted to growth in RD cells binds to decay-accelerating factor (CD55). J Virol 1995; 69:1903-1906.
17. Nowicki B, Moulds J, Hull R, Hull S: A hemagglutinin of uropathogenic Escherichia coli recognizes the Dr blood group antigen. Infect Immun 1988; 56:1057-1060.
18. Tomita M: Biochemical background of paroxysmal nocturnal hemoglobinuria. Biochim Biophys Acta 1999; 1455:269-286.
19. Piedras J, Lopez-Karpovitch X: Flow cytometric analysis of glycosylphosphatidyl-inositol-anchored proteins to assess paroxysmal nocturnal hemoglobinuria clone size. Cytometry 2000; 42:234-238.
20. Oelschlaegel U, Besson I, Arnoulet C, Sainty D, Nowak R, Noumann R, Bux Y, Enringer G: A standardized flow cytometric method for screening paroxysmal nocturnal haemoglobinuria (PNH) measuring CD55 and CD59 expression on erythrocytes and granulocytes. Clin Lab Haematol 2001; 23:81-90.
21. Pasch A, Kupper JH, Wolde A, Kandolf R, Selinka HC: Comparative analysis of virus-host cell interactions of haemagglutinating and non-haemagglutinating strains of coxsackievirus B3. J Gen Virol 1999; 80 (Pt 12):3153-3158.
22. Powell RM, Ward T, Goodfellow I, Almond JW, Evans DJ: Mapping the binding domains on decay accelerating factor (DAF) for haemagglutinating enteroviruses: implications for the evolution of a DAF-binding phenotype. J Gen Virol 1999; 80 (Pt 12):3145-3152.
23. Selinka HC, Wolde A, Pasch A, Klingel K, Schnorr JJ, Kupper JH, Lindberg AM, Kandolf R: Comparative analysis of two coxsackievirus B3 strains: putative influence of virus-receptor interactions on pathogenesis. J Med Virol 2002; 67:224-233.
24. Feuer R, Mena I, Pagarigan R, Slifka MK, Whitton JL: Cell cycle status affects coxsackievirus replication, persistence, and reactivation in vitro. J Virol 2002; 76:4430-4440.
25. Mock DM, Lankford GL, Widness JA, Burmeister LF, Kahn D, Strauss RG: Measurement of red cell survival using biotin-labeled red cells: validation against 51Cr-labeled red cells. Transfusion 1999; 39:156-162.
26. Fan JD, Wagner BL, McDonnell DP: Identification of the sequences within the human complement 3 promoter required for estrogen responsiveness provides insight into the mechanism of tamoxifen mixed agonist activity. Mol Endocrinol 1996; 10:1605-1616.
27. Heikaus S, Winterhager E, Traub O, Grummer R: Responsiveness of endometrial genes Connexin26, Connexin43, C3 and clusterin to primary estrogen, selective estrogen receptor modulators, phyto- and xenoestrogens. J Mol Endocrinol 2002; 29:239-249.
28. Yanagawa B, Spiller OB, Choy J, Luo H, Cheung P, Zhang HM, Goodfellow IG, Evans DJ, Suarez A, Yang D, Mc Manus BM: Coxsackievirus B3-associated myocardial pathology and viral load reduced by recombinant soluble human decay-accelerating factor in mice. Lab Invest 2003; 83:75-85.
29. Lyden D, Olszewski J, Feran M, Job L, Huber S: Coxsackievirus B3-induced myocarditis. Effects of sex steroids on viremia and infectivity of cardiocytes. Am J Pathol 1987; 126:432-438.
30. Hoffman GE, Le WW, Murphy AZ, Koski CL: Divergent effects of ovarian steroids on neuronal survival during experimental allergic encephalitis in Lewis rats. Exp Neurol 2001; 171:272-284.